GSK · story · 5 November
GSK · 3 headlines from 2 outlets, on 5 November 2026.
Pieces report specialty medicines driving Q3 growth while vaccines slipped, with guidance and dividend reaffirmed.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Simply Wall St is the largest at 5.8, 2.3 times AD HOC NEWS (2.5).
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Simply Wall St | 5.8 |
| AD HOC NEWS | 2.5 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Simply Wall St | 1 | +5.8 |
| AD HOC NEWS | 2 | +2.5 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +5.8 | Guidance maintained and dividend paid; valuation looks undervalued. |
| +2.5 | Specialty drugs driving growth, offset by weaker vaccines. |
| +2.5 | Specialty drugs driving growth, offset by weaker vaccines. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.